News

A Phase III trial found that pembrolizumab plus chemotherapy enhanced survival in endometrial cancer patients. A Phase III clinical trial comparing pembrolizumab to chemotherapy (carboplatin and paclitaxel) enhanced progression-free survival (PFS) in patients with stage III-IV or recurrent endometrial cancer. As...

An event that hasn’t happened before was demonstrated by researchers from Duke-NUS Medical School, colleagues in Germany, and the National Heart Centre Singapore (NHCS), suggesting that regenerative treatment to restore damaged kidney function could be a sure possibility. In...

Karolinska Institute researchers have come up with a promising antibody medication candidate for the medication of non-alcoholic fatty liver disease. There is presently no treatment for non-alcoholic fatty liver disease, which affects individuals with type 2 diabetes and can develop...

All initial clinical trial applications across the EU have to be submitted via the Clinical Trials Information System (CTIS) starting January 31, 2023. As per the European Medicines Agency (EMA), CTIS now happens to be the single-entry point for regulators...

Researchers have identified the mechanism that is responsible for the formation of cancer-associated fibroblasts, which happen to be essential for lung adenocarcinoma. Lung adenocarcinoma is the most frequent type of cancer of the lungs. It is related to cancer cells...

NUS Academic Medical Centre and SingHealth in Singapore have announced a gift of $50 million, which will be transformational, from the Lee Foundation that will aid in providing support for the advancement of research and innovation via programmes as...

The University of Freiburg researchers have found out that the release of prometastatic factors is influenced by the skeleton of the cell, known as actin. As per a research team that was led by Dr. Robert Grosse and Dr. Carsten...